about
Genetic variation in IL28B and spontaneous clearance of hepatitis C virusEffects of Peptide on NK cell-mediated MHC I recognitionKIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infectionHIV-1 adaptation to NK-cell-mediated immune pressureActivation of natural killer cells during acute infection with hepatitis C virus.Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patientsKIR/HLA interactions and pathogen immunityT cells but not NK cells are associated with a favourable outcome for resected colorectal liver metastases.A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.Hanging in the balance. KIR and their role in disease.The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways.A peptide antagonist disrupts NK cell inhibitory synapse formationSpeed and selection in the evolution of killer-cell immunoglobulin-like receptors.Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94.Understanding the host genetics of chronic hepatitis B and C.Innate and adaptive genetic pathways in HCV infection.NK cells: tuned by peptide?The allele 4 of neck region liver-lymph node-specific ICAM-3-grabbing integrin variant is associated with spontaneous clearance of hepatitis C virus and decrease of viral loads.Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C.Association of NKG2A with treatment for chronic hepatitis C virus infection.Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection.Hepatocellular carcinoma: prospects for NK cell immunotherapy?Age-related macular degeneration is associated with the HLA-Cw*0701 Genotype and the natural killer cell receptor AA haplotype.A novel antibody combination to identify KIR2DS2 NK cells in KIR2DL3/L2/S2 heterozygous donorsInhibitory killer cell immunoglobulin-like receptors strengthen CD8 T cell-mediated control of HIV-1, HCV, and HTLV-1The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activationVasoactive intestinal peptide induces proliferation of human hepatocytesNK receptors: it's all in the nameA clinical evaluation of a new method for HBV DNA quantitation in patients with chronic hepatitis BThe testing of people with any risk factor for hepatitis C in community pharmacies is cost-effectiveConserved and variable natural killer cell receptors: diverse approaches to viral infectionsImmunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis BActivating killer cell immunoglobulin-like receptors: Detection, function and therapeutic useGeneration of functional hepatocyte 3D discoids in an acoustofluidic bioreactorThe association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisActivity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma
P50
Q24596340-A54BDEA1-A969-4918-A289-E67840C4A499Q26822893-DDDDFA93-F40A-4B5B-91C8-5CF4C8F3481AQ34055276-DDAD0E06-6F79-4ED0-80E7-D112247C106FQ34205851-181039CE-F37C-4FD4-BB99-AF340FABFAD9Q34283615-7028796F-935D-484C-BC2D-0D5F7484C270Q34365617-E8B981E3-FEF8-40E6-AEA4-08017888E73AQ34401717-F2477229-2C54-4161-8B76-AFA998DF0C3FQ34565991-2E6EA9DF-29FC-487C-B543-9E8C0B9601FAQ35001169-9065E7EE-D33A-4328-8E65-70664D8B8C7BQ35119559-C9DDDA48-6218-4556-A5B2-5FA238844118Q35356926-005980D1-63A0-4A76-AB70-2A209191A88AQ36241147-8F490C3F-7685-47FC-994E-89C16447B572Q36875733-8EE304BE-54F4-4864-BAF8-555B87CA303CQ36903892-7772D185-AA11-4078-8900-CE8396C7A37BQ37086120-72C3E15B-CBDA-402B-80E3-D9763226DAA9Q37240705-709BD1D1-2946-4760-8FDD-F854B7A54B93Q37871477-74323B6F-EE40-4FD1-91A7-AECC09D00B96Q38364524-DB2F8DD3-F6AD-48A4-83D5-C0F747CADF0DQ38568884-51D61E86-DCF0-4970-A67A-77C7C3306C4AQ38997186-387C864B-E2F3-45E0-82E6-085078216821Q39141504-2A07986E-E917-4B20-BDCA-A1B9B580053DQ41682815-A9B85F40-DDAF-41A0-AC6B-447589652A01Q41930029-2E481ED4-4682-433C-8557-B7D4FCC6498AQ43944500-F2082ED2-D0F1-41E0-9572-49B4EF0E1788Q45324543-79D988B7-73DE-4DA1-9A2A-9A346178AFADQ52581296-4A076180-B1AB-4511-8929-7ED180DFB787Q54530646-1E4B66E5-F75A-47BF-BB20-8AC9305F2BF7Q58080671-26722D6A-901E-4D8E-BB62-EBBBD31AE780Q58570721-8FB3E31E-24A3-4425-8275-925BA91937E8Q61638625-4B9AF79A-4CC0-4E39-A128-54AB836E4FC5Q61719101-E48E780D-3B8B-4624-9B38-BC43B82E2244Q61719108-AF8E6E26-0347-4C12-A5FF-2040477F8665Q71773743-9119B429-DAAE-4238-9CA2-3E4DF4B39A3FQ90103568-09D3408D-C772-4E13-84DC-A43CA1F623A1Q90664677-F969AAF5-520A-4B9E-9A9D-6EC8CEBBB171Q91287934-D2EB1EEA-B03C-44D8-A5A4-8EC76282BE7EQ91393431-37849C28-8B29-41DE-8CF8-63A760BA393CQ92343377-6EB5664F-4141-46B1-93DC-6B10169ACC24Q92435702-252F82AB-3DB5-4736-8AB9-9DDEE2B8BA6FQ93361711-6245D6A5-0BDC-40DE-8073-AA49C534EA4C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Salim I Khakoo
@nl
Salim I Khakoo
@sl
Salim I. Khakoo
@en
Salim I. Khakoo
@es
type
label
Salim I Khakoo
@nl
Salim I Khakoo
@sl
Salim I. Khakoo
@en
Salim I. Khakoo
@es
prefLabel
Salim I Khakoo
@nl
Salim I Khakoo
@sl
Salim I. Khakoo
@en
Salim I. Khakoo
@es
P106
P1153
6602868240
P31
P496
0000-0002-4057-9091